Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. Almhanna K, et al. Among authors: van laethem jl. Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19. Invest New Drugs. 2017. PMID: 28527133 Clinical Trial.
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T. Almhanna K, et al. Among authors: van laethem jl. Invest New Drugs. 2017 Apr;35(2):235-241. doi: 10.1007/s10637-017-0439-y. Epub 2017 Feb 11. Invest New Drugs. 2017. PMID: 28188407 Clinical Trial.
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
Demols A, Peeters M, Polus M, Honoré P, Boterberg T, Gay F, Closon MT, Van Houtte P, Closset J, Van Laethem JL. Demols A, et al. Among authors: van houtte p, van laethem jl. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1351-6. doi: 10.1016/j.ijrobp.2005.01.043. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029792 Clinical Trial.
Emerging drugs for the treatment of pancreatic cancer.
Van Laethem JL, Marechal R. Van Laethem JL, et al. Expert Opin Emerg Drugs. 2007 May;12(2):301-11. doi: 10.1517/14728214.12.2.301. Expert Opin Emerg Drugs. 2007. PMID: 17604503 Review.
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Tabernero J, et al. Among authors: van cutsem e, van laethem jl. J Clin Oncol. 2007 Nov 20;25(33):5225-32. doi: 10.1200/JCO.2007.13.2183. J Clin Oncol. 2007. PMID: 18024868 Clinical Trial.
265 results